Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation

Leukemia Research

Volumn 28, Issue 5, 2004, Pages 461-468

  Wendelbo, Øystein ^a   Nesthus, Ingerid ^a   Sjo, Malvin ^a   Ernst, Peter ^a   Bruserud, Øystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Multiple myeloma; Peripheral blood stem cell transplantation; T lymphocytes

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY; ANTINEOPLASTIC AGENT; CD2 ANTIGEN; CD28 ANTIBODY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELPHALAN; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; MYELODYSPLASIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKOPENIA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 1842507479     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.09.007     Document Type: Article

References (28)

1. Kyle R.A. Update on the treatment of multiple myeloma. Oncologist. 6:2001;119-124.
2. Lenhoff S., Hjorth M., Holmberg E.et al. Impact on survival on high-dose chemotherapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood. 95:2000;7-11.
3. Attal H., Harousseau J.L., Stoppa A.M.et al. For the Intergroupe Francaise du Myelome: a prospective. N. Engl. J. Med. 335:1996;91-97.
4. Craig J.I., Langlands K., Parker A.C., Anthony R.S. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp. Hematol. 22:1994;898-902.
5. + cells to support single or tandem high-dose chemotherapy. Blood. 7:2000;2234-2239.
6. Barlogie B., Jagannath S., Vesole D.H.et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 3:1997;789-793.
7. Corradini P., Voena C., Astolfi M.et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests after autografting. Blood. 6:1995;1596-1602.
8. Wendelbo Ø., Glenjen N.I., Bruserud Ø. Interleukin 7 (IL7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL7 levels and IL7 responsiveness in circulating T lymphocytes. J. Interfer. Cytokine Res. 22:2002;1057-1065.
9. Van Lier R.A.W., Boot J.H., Verhoeven A.J., de Groot E.R., Brouwer M., Aarden L.A. Functional studies with anti-CD3 isotype switch-variant monoclonal antibodies. Accessory cell independent induction of interleukin 2 responsiveness in T cells by ε-anti-CD3. J. Immunol. 139:1987;2873-2879.
10. Bruserud Ø., Ulvestad E. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol. 206:2000;36-50.
11. Bloema E., Roos M.T., van Heijst J.L., Vossen J.M., Schellekens P.T. Whole blood lymphocyte cultures. J. Immunol. Methods. 122:1989;161-167.
12. Wendelbo Ø., Bruserud Ø. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay. J. Hematother. Stem. Cell. Res. 12:2003;525-536.
13. Bruserud Ø., Ulvestad E., Halstensen A., Berentsen S., Bergheim J., Nesthus I. Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia. Eur. J. Haematol. 59:1997;269-276.
14. Mackall C.L., Fleischer T.A., Brown M.R., Magrath I.T., Shad A.T., Horow M.E.et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 84:1994;2221-2228.
15. Bruserud Ø., Ulvestad E. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. J. Interferon. Cytokine Res. 20:2000;947-954.
16. Giarratana M.C., Verge V., Schmitt C., Bertho J.M., Kobari L., Barret C.et al. Presence of primitive lymphoid progenitors with NK and B potential in ex vivo expanded bone marrow cell cultures. Exp. Hematol. 28:2000;46-54.
17. Curti A., Fogli M., Ratta M., Tura S., Lemoli R.M. Stem cell factor and Flt3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors. J. Immunol. 166:2001;848-854.
18. Shinjo K., Takehashita A., Ohnishi K., Ohno R. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk. Lymphoma. 25:1997;37-46.
19. Mackall C.L., Stein D., Fleischer T.A., Brown M.R., Hakim F.T., Bare C.V.et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 96:2000;754-762.
20. + hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia. Cancer Res. 59:1999;2150-2158.
21. Talmadge J.E., Reed E., Ino K.et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 19:1997;161-172.
22. + cell transplantation. Bone Marrow Transplant. 25:2000;1249-1255.
23. Guillaume T., Rubinstein D.B., Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 5:1998;1471-1490.
24. Harris N.L., Jaffe E.S., Diebold J.et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 12:1999;3835-3849.
25. Abbas AK, Pober JS, Antigen processing and presentation to T lymphocytes. In: Cellular and molecular immunology; 2000. p. 69-83.
26. Volpi I., Perruccio K., Tosti A.et al. Post-grafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 97:2001;2514-2521.
27. Bruserud Ø., Wendelbo Ø. Biological treatment in acute myelogenous leukemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Exp. Opin. Biol. Ther. 1:2001;1005-1016.
28. Akpek G., Lenz G., Lee S.M.et al. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant. 28:2001;1105-1109.